Long-term use and tolerability of irbesartan for control of hypertension

In this review, we discuss the pharmacological and clinical properties of irbesartan, a noncompetitive angiotensin II receptor type 1 antagonist, successfully used for more than a decade in the treatment of essential hypertension. Irbesartan exerts its antihypertensive effect through an inhibitory e...

Full description

Bibliographic Details
Main Authors:	Forni, Valentina, Wuerzner, Grégoire, Pruijm, Menno, Burnier, Michel
Format:	Online
Language:	English
Published:	Dove Medical Press 2011
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3172075/

id	pubmed-3172075
recordtype	oai_dc
spelling	pubmed-31720752011-09-26 Long-term use and tolerability of irbesartan for control of hypertension Forni, Valentina Wuerzner, Grégoire Pruijm, Menno Burnier, Michel Review In this review, we discuss the pharmacological and clinical properties of irbesartan, a noncompetitive angiotensin II receptor type 1 antagonist, successfully used for more than a decade in the treatment of essential hypertension. Irbesartan exerts its antihypertensive effect through an inhibitory effect on the pressure response to angiotensin II. Irbesartan 150–300 mg once daily confers a lasting effect over 24 hours, and its antihypertensive efficacy is further enhanced by the coadministration of hydrochlorothiazide. Additionally and partially beyond its blood pressure-lowering effect, irbesartan reduces left ventricular hypertrophy, favors right atrial remodeling in atrial fibrillation, and increases the likelihood of maintenance of sinus rhythm after cardioversion in atrial fibrillation. In addition, the renoprotective effects of irbesartan are well documented in the early and later stages of renal disease in type 2 diabetics. Furthermore, both the therapeutic effectiveness and the placebo-like side effect profile contribute to a high adherence rate to the drug. Currently, irbesartan in monotherapy or combination therapy with hydrochlorothiazide represent a rationale pharmacologic approach for arterial hypertension and early-stage and late-stage diabetic nephropathy in hypertensive type II diabetics. Dove Medical Press 2011-04-18 /pmc/articles/PMC3172075/ /pubmed/21949635 http://dx.doi.org/10.2147/IBPC.S12211 Text en © 2011 Forni et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Forni, Valentina Wuerzner, Grégoire Pruijm, Menno Burnier, Michel
spellingShingle	Forni, Valentina Wuerzner, Grégoire Pruijm, Menno Burnier, Michel Long-term use and tolerability of irbesartan for control of hypertension
author_facet	Forni, Valentina Wuerzner, Grégoire Pruijm, Menno Burnier, Michel
author_sort	Forni, Valentina
title	Long-term use and tolerability of irbesartan for control of hypertension
title_short	Long-term use and tolerability of irbesartan for control of hypertension
title_full	Long-term use and tolerability of irbesartan for control of hypertension
title_fullStr	Long-term use and tolerability of irbesartan for control of hypertension
title_full_unstemmed	Long-term use and tolerability of irbesartan for control of hypertension
title_sort	long-term use and tolerability of irbesartan for control of hypertension
description	In this review, we discuss the pharmacological and clinical properties of irbesartan, a noncompetitive angiotensin II receptor type 1 antagonist, successfully used for more than a decade in the treatment of essential hypertension. Irbesartan exerts its antihypertensive effect through an inhibitory effect on the pressure response to angiotensin II. Irbesartan 150–300 mg once daily confers a lasting effect over 24 hours, and its antihypertensive efficacy is further enhanced by the coadministration of hydrochlorothiazide. Additionally and partially beyond its blood pressure-lowering effect, irbesartan reduces left ventricular hypertrophy, favors right atrial remodeling in atrial fibrillation, and increases the likelihood of maintenance of sinus rhythm after cardioversion in atrial fibrillation. In addition, the renoprotective effects of irbesartan are well documented in the early and later stages of renal disease in type 2 diabetics. Furthermore, both the therapeutic effectiveness and the placebo-like side effect profile contribute to a high adherence rate to the drug. Currently, irbesartan in monotherapy or combination therapy with hydrochlorothiazide represent a rationale pharmacologic approach for arterial hypertension and early-stage and late-stage diabetic nephropathy in hypertensive type II diabetics.
publisher	Dove Medical Press
publishDate	2011
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3172075/
_version_	1611475349000945664

Long-term use and tolerability of irbesartan for control of hypertension

Similar Items